MitoGel™ is potentially the first non-surgical, renal-sparing, local treatment for low-grade UTUC. MitoGel is a sustained release formulation of Mitomycin C in the upper urinary tract. UroGen has obtained Orphan Drug Designation for MitoGel for UTUC.

Read More >

VesiGel™ is potentially the first non-surgical, local chemoablation therapy for the treatment Low Grade NMIBC. VesiGel is a sustained release formulation of high dose Mitomycin C for the effective delivery and prolonged tissue exposure.

Read More >

Vesimune™ is a TLR-7 agonist-based formulation for local intravesical delivery.  Vesimune is being developed as a potential treatment for CIS. UroGen has obtained Orphan Drug Designation for Vesimune for the treatment of CIS.

 

Read More >

About UroGen Pharma

UroGen Pharma (“UroGen” or the “Company”) is a clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies with a focus on uro-oncology. The lead drug candidates, MitoGel and VesiGel, are designed to potentially remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade bladder cancer and low-grade upper tract urothelial carcinoma, or UTUC.  In addition, UroGen is developing two additional clinical-stage drug candidates, Vesimune, for the treatment of high-grade non-muscle invasive bladder cancer and BotuGel, for the treatment of overactive bladder and interstitial cystitis.

Read More >

Clinical Trials

UTUC

olympusThe OLYMPUS study

Optimized DeLivery of Mitomycin for Primary UTUC Study
CURRENTLY RECRUITING CENTERS IN THE US AND EUROPE

 

BLADDER CANCER

optimaThe OPTIMA study

OPTimized Instillation of Mitomycin for BlAdder Cancer Treament
COMPLETED PATIENT RECRUITMENT